Don't pay just to have an ISA. Find out more
(ABH.L) Angel Biotechnology Holdings PLC Buy/Sell
Add to portfolio Set Alert Level 2 Desktop Trader
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Date/Time | Headline | Source |
|---|---|---|
| 18-03-10 | RNS |
|
|
RNS Number : 7624I Angel Biotechnology Holdings Plc 18 March 2010
ANGEL BIOTECHNOLOGY HOLDINGS PLC ("Angel" or "the Company") Angel announces GMP contracts with ReNeuron Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce signing of two new manufacturing contracts with ReNeuron Group plc. ReNeuron is gearing up to begin a ground-breaking clinical study in stroke patients with its ReN001 stem cell therapy for which it recently received final regulatory approval. The new contracts support ReNeuron's clinical trial activities by the manufacture of additional clinical-grade material (drug substance lots) and the provision of manufacturing process validation services. The value of the contracts was not disclosed. As previously notified, Angel has been named as ReNeuron's manufacturing partner for this first-in-man clinical trial. Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "We are very pleased to have signed these contracts to provide ReNeuron with additional GMP grade materials and services in support of its ReN001 clinical trial for stroke. Such clinical programmes are complex and require a high level of regulatory compliance. Angel's significant experience and expertise in this rapidly evolving field provides the flexible and regulatory compliant solutions that Biotech and Pharma customers require in the cell therapy arena. Our premier offering has made Angel the leading GMP manufacturer for clinical grade stem cells in the UK and beyond."
For further information, please call:
Angel Biotechnology Holdings plc Tel: +44 (0) 131 445 6077
Grant Thornton Corporate Finance Tel: +44 (0) 20 7383 5100
Philip Secrett, Colin Aaronson
Steve Cox/Stephen Waterman About Angel Biotechnology Holdings plc Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services, GMP manufacturing for advanced biologics and regulatory support including preparation of dossiers for regulatory submissions. We have a global business supporting biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. Angel specializes in the provision of advanced biologics including autologous and allogeneic cell therapy products including stem cells and cellular vaccines, specific purified natural and recombinant proteins and bacteriophage. Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag. Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at www.angelbio.com. About ReNeuron Group plc ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has regulatory approval for a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. Patient recruitment for this trial is expected to commence shortly. The company is also developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina. ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com. This information is provided by RNS The company news service from the London Stock Exchange END
MSCKKODDCBKDKND More |
||
| 10-02-10 | RNS |
|
|
RNS Number : 9567G Angel Biotechnology Holdings Plc 10 February 2010 10 February 2010 Angel Biotechnology Holdings plc (the "Company") Exercise of warrants The Company announces that application has been made for the admission to trading on AIM of 714,285 ordinary shares of 0.1p ("Ordinary Shares") nominal value with admission expected to take place on 12 February 2010. The shares have been issued following the exercise of warrants at a price of 0.175p per share. Following the issue of these shares to trading on AIM, the Company will have a total of 2,081,840,467 Ordinary Shares in issue with voting rights. The Company has no shares in treasury.
For further information:
Dr Paul Harper, Chairman
Philip Secrett / Colin Aaronson
This information is provided by RNS The company news service from the London Stock Exchange END
LISGMGMZFGGGGZM More |
||
| 08-02-10 | RNS |
|
|
RNS Number : 7666G Angel Biotechnology Holdings Plc 08 February 2010
ANGEL BIOTECHNOLOGY HOLDINGS PLC ("Angel" or "the Company") Angel announces contract with Progenteq Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the signing of a contract with Progenteq Limited, a Fusion IP spin-out company from Cardiff University. Progenteq is developing a novel cell therapy for the treatment of acute knee injuries. Under the contract, Angel will provide consultancy and development services for Progenteq's novel cartilage replacement therapy. The terms of the contract have not been disclosed. Commenting on the contract, Gordon Sherriff, Angel's Chief Operating Officer said: "We are delighted to be working with Progenteq on its novel cell therapy. Being awarded this contract further acknowledges our experience and expertise in the field of regenerative medicine development and manufacturing. Angel's detailed understanding of the regulatory framework for GMP compliance with such therapies has played a key role in being awarded this contact. We are always pleased to be able to offer consultancy services in addition to our manufacturing offering ". Dominic Griffiths, Director of Progenteq said: "We are tremendously excited by the prospect of this novel cell therapy. Angel is well placed to assist the company in its product development activities and we look forward to working with them as we progress Progenteq towards the clinic."
For further information, please call:
Angel Biotechnology Holdings plc Tel: +44 (0) 131 445 6077
Grant Thornton Corporate Finance Tel: +44 (0) 20 7383 5100
Philip Secrett, Colin Aaronson
Steve Cox/Stephen Waterman About Angel Biotechnology Holdings plc Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services, GMP manufacturing for advanced biologics and regulatory support including preparation of dossiers for regulatory submissions. We have a global business supporting biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. Angel specializes in the provision of advanced biologics including autologous and allogeneic cell therapy products including stem cells and cellular vaccines, specific purified natural and recombinant proteins and bacteriophage. Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag. Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at www.angelbio.com. About Progenteq Progenteq was established by Fusion IP to develop a novel cartilage replacement therapy that has the potential to revolutionise the treatment of acute knee injuries. The Company is founded on the work of Professor Charlie Archer's research group at Cardiff University's School of Biosciences. Professor Archer is Head of the Connective Tissue Biology Group, a leading centre of excellence for tissue engineering and repair. The group has successfully isolated a defined population of cells from the articular cartilage which surround the main bones in the knee joint. These cells display stem-cell like properties and can be expanded in the laboratory to produce very large quantities of cartilage. As a result this cell type could provide an ideal source of material for an "allogeneic" cartilage replacement therapy, whereby cells derived from donors can be taken and used to grow a large tissue bank of cartilage that can be stored and is suitable for insertion into patients with acute knee injuries as and when needed. This model promises a more cost-effective cell therapy than current "autologous" approaches, where cells are removed from a patient, expanded and then implanted into the same patient. The successful development of a cartilage cell bank could also pave the way for treatment of degenerative cartilage damage such as that seen in osteoarthritis. The company was established out of Fusion IP plc's exclusive spin-out agreement with Cardiff University. This information is provided by RNS The company news service from the London Stock Exchange END
CNTUGUWUPUPUGCA More |
||
| 03-02-10 | RNS |
|
|
RNS Number : 5784G Angel Biotechnology Holdings Plc 03 February 2010
ANGEL BIOTECHNOLOGY HOLDINGS PLC ("Angel" or "the Company") Placing Placing Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce that it has placed through Hybridan LLP ("Hybridan") 570,200,000 ordinary shares of 0.1 pence each at 0.25 pence per share to raise £1,425,500 before expenses. The proceeds of the placing will be used to provide working capital and to fund capital expenditure at the Company's facility in Edinburgh to meet increasing demand for the Company's products and services. Further details of the Placing are set out below. In addition, Paul Harper, Chairman of Angel, has agreed to take 20,000,000 shares at 0.25 pence per share in payment of amounts owing to him by the Company. By virtue of its size, this issue of shares to Dr Harper consitutes a related party transaction under Rule 13 of the AIM Rules for Companies. The independent directors of the Company, having consulted with its nominated adviser, consider that the terms of the transaction are fair and reasonable insofar as shareholders are concerned. Application has been made to the London Stock Exchange for the 590,200,000 new shares ("New Shares") to be admitted to trading on AIM and it is expected that admission will become effective and trading will commence on 8 February 2010. The new shares will rank pari passu with the existing ordinary shares of the Company. Following the admission of the New Shares to trading on AIM, the Company will have a total of 2,081,126,182 shares in issue with voting rights. The Company has no shares in treasury. Following the issue of these shares, Paul Harper will hold 80,348,884 shares representing 3.9 per cent. of the Company's total voting rights. Cell therapy and regenerative medicine grant awards On 18 January 2010, the Company announced its involvement in 3 grant awards in the cell therapy and regenerative medicine fields. In this regard, the Company is also pleased to acknowledge the Technology Strategy Board's Press release entitled. "REGENERATIVE MEDICINE RESEARCH AND DEVELOPMENT TO RECEIVE £4.5 MILLION FUNDING INJECTION" which names Angel as a collaborator with Pfizer Regenerative Medicine as one of the consortia sharing the £2.8m which is the first phase of this investment. The Pfizer/Angel programme is one of three programmes highlighted in the announcement, from the 30 programmes funded at this stage. Commenting on the press release, Gordon Sherriff, Angel's Chief Operating Officer said: "Angel is extremely pleased to be involved in 3 of the 30 feasibility studies funded by the TSB. The TSB's significant investment of £2.8M reflects the government's commitment to developing growth in the area of regenerative medicine and continues to place Angel at the forefront of development and manufacturing for novel cell-based therapies." Dr Paul Harper, Chairman, commented: "I am pleased at the support that the Company has received from new and existing investors in raising the funds required to fund both a substantially increased level of business activity and our plans to increase the capacity of the Pentlands facility. The Directors believe that this will provide the means by which the Company should move into profitability" Enquiries:
Claire Noyce/Kelly Gardiner
Philip Secrett/Colin Aaronson
Steve Cox/Steve Waterman About Angel Biotechnology Holdings plc Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and GMP manufacturing for advanced biologics, supporting biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.Angel specializes in the provision of advanced biologics including autologous and allogeneic cell therapy products including stem cells and cellular vaccines, specific purified natural and recombinant proteins and bacteriophage. Angel is managed by a team with wide ranging experience in biopharmaceutical manufacture, gained in companies such as Glaxo, Johnson and Johnson, Serologicals Inc., PPL Therapeutics and Intercell Ag. Angel was admitted to trading on AIM in November 2005. More information about the Company can be found at www.angelbio.com. Further details of the Placing The Company has entered into a placing agreement containing standard provisions and pursuant to which the Company has agreed that for 12 months it will not issue shares or options or enter into a material transaction outside of the ordinary course of business without the prior written consent of Hybridan (such consent not to be unreasonably withheld or delayed) or to draw down any sums for a period of 12 months under the Committed Equity Facility announced on 23 November 2009. This information is provided by RNS The company news service from the London Stock Exchange END
IOEBIGDDGGGBGGD More |
||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| 17:34 |
1
|
|||
|
| ||||
|
| ||||
|
I've been trying not to respond in any way to the queen of the cut and paste since I put her on ignore. And as a rule I do not to read any of her posts.
I posted this over a month ago. “For the sake of my sanity can you please stop trying to reason with the woman, she's not listening. I feel sorry for her loss, really I do but come on, enough already. Yesterday there were six pages of this, 35% from her and 60% from people responding. Maybe 3 posts ABH related." A month on and nothing has changed, if anything it's getting worse. I’m in two minds whether to post this as by doing so I’m perpetuating the situation. I know I have done so in the past. I'm aware that there are always going to be newcomers that are going to respond and others that won’t let sleeping trolls lie. As well as previous holders popping in for a visit. It’s a shame that, as in F&V’s post, it is then used further her cause. As it was an interesting post. It’s healthy to have a balanced viewpoint on these boards. And there should be room for everyone’s point of view. But within reason surely. Indeed, there have been those with the knowledge and patience to answer the questions posed as did Worlitzer and even that had no effect. I have come to the conclusion that there is absolutely nothing you can say or do that is going to make a blind bit a difference, bearing inventing a time machine and taking her back to the day she did the T3 that went so wrong and put her in this position. It states on the discussion home page of this website that these boards are to meet people from all walks of life, compare different investment strategies, share knowledge, validate decisions (or not) and have some fun. I don’t think that one person should be able or allowed to completely take over a board like this. Even though I’m a holder and don’t particularly want to see the SP to go down, I wouldn’t personally class myself as a ramper. Positive, yes, but then why would you want to cut the branch you’re sat on. I was happy to have bought in to ABH when I did 12 months ago. I’m happy to have averaged down and I will continue to hold till such time as I see fit. The decision at all points along the way has been mine and mine alone. And if I am wrong and loose all my money guess who I’ll blame. Yes you J... , no. Just me. And You can indeed say, " I told you so". At the moment this board is like someone trying to argue with one of those recorded messages on the phone. No matter how much you shout it keeps saying the same thing. But this one also learns new messages from your augments and adds them to the recorded messages that you’re arguing about. (ad infinitum) Break the cycle. Si |
||||
| 12:34 |
1
|
|||
|
| ||||
|
| ||||
|
I've just added her to my ignore list. Wish I'd known I could do it sooner! Sorry for mentioning her to all those who have already put her onto there ignore list.
I will however take this last opportunity to say, JaneW1 why not post on other discussions looking back apart from the odd Rene post it's ABH only. In response to her comments yesterday to me, I clearly am foolish and because that was my first ever post it is obvious that I am new to dealing and in fact have not been doing it for years! Sorry for not replying sooner but I didn't have the time to write 25 posts yesterday. Seriously as I've thought all along since investing, this is a company in a market with huge growth potential. It is still early days for Angel, but in the long run, 5+ years they have the potential to make its current share holders a lot of money. I am in for the long run! Finally, Jane please feel free to reply, insult etc, I cannot see what you are writing any more. |
||||
| 11:53 |
2
|
|||
|
| ||||
|
| ||||
|
Jane, I've been following this board for a good while now and you seem to have gone full circle, I recall your daily bashing which for some reason turned into constant ramping and has now gone back to bashing again.
You put so much effort into writing posts nobody is interested in reading. |
||||
| 11:50 |
4
|
|||
|
| ||||
|
| ||||
|
She's been on my ignore list for many months. Really irritating to even have to see her name mentioned and can't believe any of you take her seriously.
Let's try an experiment. Everybody put her on ignore and see if she stops posting. C'mon just try it. |
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Discussion Board Terms & Conditions FSA Market Abuse Fact Sheet
More...